Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Marker Therapeutics Inc (MRKR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.90-11.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MRKR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Extend cash runway through Q4 2026 | It aims to extend cash through Q4 2026. | Intact | Cash runway falls short of Q4 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story, not an established earnings compounder: MRKR is loss-making, recent financial performance is weak, and overall risk is high. The thesis is in a watch state, with management priorities focused on advancing MT-601 and extending runway through 2026-Q4, but substantive progress is not yet clear from the supplied evidence.
The valuation model describes MRKR as cheap versus peers, while also showing a 51% premium versus peers and low model confidence, so the valuation signal is mixed. The expectations gap is negative, which points to limited support from expectations, but the evidence does not specify exactly what the market assumes.
Near term, loss-making results and elevated risk of an earnings miss leave performance vulnerable, even though MRKR reported earnings beats in March 2026 and November 2025. Management has stated priorities around MT-601, financial resources, and runway, but the supplied figures do not establish substantive progress this quarter. The Healthcare sector backdrop has improved, though this does not resolve MRKR’s weak company-level performance.
The multi-year view hinges on whether MRKR advances MT-601 in pancreatic cancer and extends its cash runway through 2026-Q4. Near term, a guidance cut would be a negative signal, while continued strength among Healthcare bellwethers could support the sector backdrop. Weaker employment data could also increase recession concerns and pressure cyclical names.
Over the next 1 to 3 years, MRKR remains a high-risk thesis with limited evidence of clinical delivery and weak recent financial performance; the improving sector context is a counterweight, not a substitute for company progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Marker Therapeutics Inc's published investment case. The stated target is Maintain stable management status. |
| Intact |
| Significant management instability or turnover |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Improve revenue generation | A primary condition in Marker Therapeutics Inc's published investment case. The stated target is Revenue growth above -50% next year. | Improving | Revenue growth falls below -50% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.01 → $-0.88 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-07-25 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-07-26 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-07-27 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-07-28 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-07-29 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-07-30 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-07-31 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-01 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-02 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-03 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-04 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-05 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-06 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-07 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-08 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-09 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-10 | $-0.76 | $20,085,670 | 2 / 3 |
| 2026-08-12 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-13 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-14 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-15 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-16 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-17 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-18 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-19 | $-1.01 | $20,085,767 | 2 / 2 |
| 2026-08-20 | $-1.03 | $20,085,667 | 2 / 2 |
| 2026-08-21 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-22 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-23 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-24 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-25 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-26 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-27 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-28 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-29 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-30 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-08-31 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-01 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-02 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-03 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-04 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-05 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-06 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-07 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-08 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-09 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-10 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-11 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-12 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-13 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-14 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-15 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-16 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-17 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-18 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-19 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-20 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-21 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-22 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-23 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-24 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-25 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-26 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-27 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-28 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-29 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-09-30 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-01 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-02 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-03 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-04 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-05 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-06 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-07 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-08 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-09 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-10 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-11 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-12 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-13 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-14 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-15 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-16 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-17 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-18 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-19 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-20 | $-0.88 | $20,185,767 | 2 / 2 |
| 2026-10-21 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-22 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-23 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-24 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-25 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-26 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-27 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-28 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-29 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-30 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-10-31 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-11-01 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-11-02 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-11-03 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-11-04 | $-0.88 | $20,185,667 | 2 / 2 |
| 2026-11-05 | $-0.88 | $20,185,667 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.